The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective-Reference-Cited by-同舟云学术

The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2−negative metastatic breast cancer: experience from the patient perspective

Published:2014-08-18 Issue:6 Volume:14 Page:929-940
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Gupta Shaloo,Zhang Jie,Jerusalem Guy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1586/14737167.2014.949243

Reference34 articles.

1. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Incidence of Breast Cancer With Distant Involvement Among Women in the United States, 1976 to 2009

3. Effect of HER2 status on distant recurrence in early stage breast cancer

4. International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy

5. Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women With Early-Stage Breast Cancer

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease landscape of advanced HER2-breast cancer patients by treatment line in three EU countries and USA;Future Oncology;2024-05-17

2. Real-world effectiveness of CDK4/6 inhibitors on patients with HR+/HER2– advanced breast cancer in South Korea, focusing on underrepresented patients;Current Medical Research and Opinion;2024-05-09

3. Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer;Frontiers in Oncology;2023-10-18

4. Understanding Patient Preferences Regarding the Important Determinants of Breast Cancer Treatment: A Narrative Scoping Review;Patient Preference and Adherence;2023-10

5. An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer;Clinical Cancer Research;2023-06-01